POSIMIR
Peakbupivacaine
NDAINFILTRATIONSOLUTION
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
POSIMIR (bupivacaine) is nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 2021.
Drug data last refreshed 5d ago
Mechanism of Action
nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain
Started Jan 2026
200 enrolled
Pain Management
Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.
Started Jul 2025
408 enrolled
Anal Fistula
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Started Oct 2024
200 enrolled
Breast Cancer
Comparative Analysis of Hypobaric Versus Hyperbaric Bupivacaine for Spinal Anesthesia in Day-Case Anorectal Surgery
Started Feb 2022
Hyperbaric Prilocaine Compared With Hyperbaric Bupivacaine in Cervical Cerclage?
Started Aug 2021
135 enrolled
Cervical Incompetence in Pregnancy as Antepartum Condition
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.